Erythromycin + Zinc acetate

Generic Medicine Info
Indications and Dosage
Acne vulgaris
Adult: As soln: Apply bid to the affected area for 10-12 wk.
Child: Same as adult dose.
Elderly: Same as adult dose.
Hypersensitivity to erythromycin, zinc acetate, or other macrolide antibiotics.
Adverse Reactions
Rarely, hypersensitivity, pruritus, dry skin, erythema; skin irritation, burning sensation and exfoliation.
Patient Counseling Information
Avoid contact w/ eyes or mucous membranes of the nose and mouth.
Symptoms: Idiosyncratic hypersensitivity. Management: Wash the treated area w/ copious water and simple soap.
Drug Interactions
May occur cross resistance w/ other macrolide group antibiotics, and w/ lincomycin and clindamycin.
Description: Erythromycin exerts its antibacterial activity by inhibiting RNA-dependent protein synthesis at the chain elongation step. It binds to 50S ribosomal subunit which blocks transpeptidation. Zinc induces copper binding protein metallothionein production in enterocytes. Copper binding w/in enterocytes may impair intestinal absorption of dietary copper and reabsorption of endogenously secreted copper in saliva, bile, gastric acid.
Onset: Zinc: Slow.
Absorption: Penetrates independently.
Store below 25°C.
MIMS Class
Acne Treatment Preparations
ATC Classification
D10AF52 - erythromycin, combinations ; Belongs to the class of topical antiinfective preparations used in the treatment of acne.
Anon. Erythromycin (Topical). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 16/03/2016.

Anon. Zinc acetate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 16/03/2016.

Joint Formulary Committee. Erythromycin with Zinc acetate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 16/03/2016.

Disclaimer: This information is independently developed by MIMS based on Erythromycin + Zinc acetate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in